Relay Therapeutics, INC Form 4 insider transactions

Relay Therapeutics CEO, Sanjiv Patel, sold 375,000 shares of common stock through a family trust over three days, according to a recent SEC filing.

Peter Rahmer, Chief Corporate Development Officer at Relay Therapeutics, was granted stock options for 275,000 shares.

Brian Adams, Chief Legal Officer of Relay Therapeutics, acquired 275,000 stock options on January 10, 2025, which vest quarterly over four years.

Relay Therapeutics CEO, Sanjiv Patel, was granted 1.1 million stock options on January 10, 2025, which vest quarterly over four years.

Donald A. Bergstrom, President of R&D at Relay Therapeutics, was granted stock options for 400,000 shares of common stock.

Relay Therapeutics' Chief Financial Officer, Thomas Catinazzo, was granted 275,000 stock options on January 10, 2025, which vest quarterly over four years.

A Relay Therapeutics executive sold shares to cover tax obligations from vested stock units and under a pre-arranged 10b5-1 trading plan.

Brian Adams, Chief Legal Officer of Relay Therapeutics, sold 299 shares of common stock on December 27, 2024, to cover income tax withholding obligations upon the vesting of restricted stock units.

Donald A. Bergstrom, President of R&D at Relay Therapeutics, sold 657 shares of common stock to cover income tax withholding obligations upon the vesting of restricted stock units.

Thomas Catinazzo, CFO of Relay Therapeutics, sold shares to cover income tax withholding obligations and pursuant to a pre-arranged Rule 10b5-1 trading plan.

Peter Rahmer, Chief Corporate Development Officer of Relay Therapeutics, sold 400 shares of common stock on December 27, 2024, to cover income tax withholding obligations upon the vesting of restricted stock units.

Relay Therapeutics' CEO, Sanjiv Patel, sold 100,000 shares of common stock at $5 per share on December 16, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Peter Rahmer, Chief Corporate Development Officer at Relay Therapeutics, sold 1,621 shares of common stock to cover income tax withholding obligations upon the vesting of restricted stock units.

Thomas Catinazzo, CFO of Relay Therapeutics, sold shares of common stock to cover income tax withholding obligations and under a pre-arranged Rule 10b5-1 trading plan.

Donald A. Bergstrom, President of R&D at Relay Therapeutics, sold shares to cover income tax withholding obligations upon the vesting of restricted stock units.

Brian Adams, Chief Legal Officer of Relay Therapeutics, sold 1,632 shares of common stock on October 28, 2024, to cover income tax withholding obligations upon the vesting of restricted stock units.

Peter Rahmer, Chief Corporate Development Officer of Relay Therapeutics, sold 245 shares of common stock on September 27, 2024, to cover income tax withholding obligations upon the vesting of restricted stock units.

Thomas Catinazzo, CFO of Relay Therapeutics, sold shares of common stock on September 27, 2024, to cover income tax withholding obligations and under a pre-arranged Rule 10b5-1 trading plan.

Donald A. Bergstrom, President of R&D at Relay Therapeutics, sold 648 shares of common stock to cover income tax withholding obligations upon the vesting of restricted stock units.

Brian Adams, Chief Legal Officer of Relay Therapeutics, sold 295 shares of common stock on September 27, 2024, to cover income tax withholding obligations upon the vesting of restricted stock units.

Thomas Catinazzo, CFO of Relay Therapeutics, sold shares of common stock to cover income tax withholding obligations and under a pre-arranged 10b5-1 trading plan.

Peter Rahmer, Chief Corporate Development Officer of Relay Therapeutics, sold shares of common stock between July 29 and July 31, 2024, to cover tax obligations and under a pre-arranged 10b5-1 trading plan.

Donald A. Bergstrom, President of R&D at Relay Therapeutics, sold 2,698 shares of common stock to cover income tax withholding obligations upon the vesting of restricted stock units.

Brian Adams, Chief Legal Officer of Relay Therapeutics, sold 1,638 shares of common stock to cover income tax withholding obligations upon the vesting of restricted stock units.

Relay Therapeutics' CEO, Sanjiv Patel, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Relay Therapeutics CEO Sanjiv Patel acquired 2,108 shares of common stock through the company's Employee Stock Purchase Plan (ESPP) at a price of $5.54 per share.

Donald A. Bergstrom, President of R&D at Relay Therapeutics, sold 648 shares of common stock to cover income tax withholding obligations upon the vesting of restricted stock units.

Peter Rahmer, Chief Corporate Development Officer at Relay Therapeutics, reports the sale of 245 shares to cover tax obligations and the purchase of 2,108 shares under the company's Employee Stock Purchase Plan.

Relay Therapeutics' CFO, Thomas Catinazzo, sold shares of common stock on June 27, 2024, to cover income tax withholding obligations related to vesting restricted stock units.

Brian Adams, Chief Legal Officer of Relay Therapeutics, sold 295 shares of common stock on June 27, 2024, to cover income tax withholding obligations upon the vesting of restricted stock units.